Altasciences rebrands its web of CROs in hopes of standing out

Canada's Altasciences is rebranding its three portfolio CROs in an effort to differentiate itself on the market for early-stage clinical research.

The company--which operates Algorithme Pharma, Vince and Associates Clinical Research and Algorithme Pharma USA--is uniting its divisions under the Altasciences logo, maintaining their individual names but promoting them as a single entity. The idea is "to bring to the market one unified look that better represents our seamless internal processes and close-knit teams," Altasciences CEO Chris Perkin said in a statement.

Combined, the companies have more than 600 beds for Phase I studies at facilities in the U.S. and Canada, Altasciences said, and the conglomerate bills itself as the largest early-phase clinical CRO in North America.

Altasciences, owned by Kilmer Capital Partners, became the umbrella company of the long-standing Algorithme after buying Vince and Associates in 2013. The company launched Algorithme Pharma USA the following year and has presided over the three companies ever since.

Despite the rebrand, Perkin said, "Altasciences' mission remains the same, which is to provide the best quality early stage clinical development services to an international customer base of pharmaceutical, biotechnology and generic companies with a focus on customer service."

- read the statement

Suggested Articles

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.